Estimating the Reliability and Validity of the Upper Extremity Functional Index in Women After Breast Cancer Surgery.

BACKGROUND: Activity limitations as well as impairments such as pain, numbness, limitation of shoulder range of motion, and weakness are common and well documented during and after treatment for breast cancer. There is limited information regarding the measurement properties of patient-reported outcome measures of upper extremity activity limitation in this population. This study examined the reliability and validity of the Upper Extremity Functional Index (UEFI) in patients after surgery for breast cancer. PATIENTS AND METHODS: Measures of function, shoulder flexion range of motion, and pain were obtained for 53 women before and 2 weeks after surgery for breast cancer. To estimate UEFI test-retest reliability, a convenience sample of 20 patients was assessed on a second occasion within 48 hours of their 2-week postsurgery assessment. Convergent and discriminant construct validation methods were applied by examining correlations between UEFI scores and change scores with those of the shortened version of the Disabilities of the Arm, Shoulder and Hand (QuickDASH), Functional Assessment of Cancer Therapy-Breast (FACT-B) +4 items, shoulder flexion range, and pain. RESULTS: UEFI test-retest reliability was estimated to be 0.87 (95% confidence interval, 0.69, 0.94), and the standard error of measurement was 4.8 (95% confidence interval, 3.7, 7.1) scale points. The 90% confidence interval for a given UEFI score was ±7.9 and minimal detectable change at 90% confidence (MDC90) was ±11.1 points. UEFI correlations with the QuickDASH (cross-sectional -0.79 and longitudinal -0.62) were greater than with the FACT-B+4 and impairment measures. CONCLUSION: These results support and guide the use of the UEFI in patients after breast cancer surgery.

Ultrasound 2D strain measurement for arm lymphedema using deformable registration: A feasibility study.

PURPOSE: Lymphedema, a swelling of the extremity, is a debilitating morbidity of cancer treatment. Current clinical evaluation of lymphedema is often based on medical history and physical examinations, which is subjective. In this paper, the authors report an objective, quantitative 2D strain imaging approach using a hybrid deformable registration to measure soft-tissue stiffness and assess the severity of lymphedema. METHODS: The authors have developed a new 2D strain imaging method using registration of pre- and post-compression ultrasound B-mode images, which combines the statistical intensity- and structure-based similarity measures using normalized mutual information (NMI) metric and normalized sum-of-squared-differences (NSSD), with an affine-based global and B-spline-based local transformation model. This 2D strain method was tested through a series of experiments using elastography phantom under various pressures. Clinical feasibility was tested with four participants: two patients with arm lymphedema following breast-cancer radiotherapy and two healthy volunteers. RESULTS: The phantom experiments have shown that the proposed registration-based strain method significantly increased the signal-to-noise and contrast-to-noise ratio under various pressures as compared with the commonly used cross-correlation-based elastography method. In the pilot study, the strain images were successfully generated for all participants. The averaged strain values of the lymphedema affected arms were much higher than those of the normal arms. CONCLUSIONS: The authors have developed a deformable registration-based 2D strain method for the evaluation of arm lymphedema. The initial findings are encouraging and a large clinical study is warranted to further evaluate this 2D ultrasound strain imaging technology.

Implementing the Prospective Surveillance Model (PSM) of Rehabilitation for Breast Cancer Patients with 1-Year Postoperative Follow-up, a Prospective, Observational Study.

BACKGROUND: The Prospective Surveillance Model (PSM) of rehabilitation for patients with breast cancer aims for early identification, treatment, and support of physical impairments postoperatively. The purpose of this study was to describe the incidence of impairments during the first postoperative year and the differences between the patients requiring rehabilitation intervention versus those not requiring intervention. METHODS: A total of 120 patients were enrolled. Impairment measures included: pain, range of motion, and self-reported measures of function using the Upper Extremity Functional Index (UEFI) and Quick Disability of the Arm, Shoulder and Hand (QuickDASH) questionnaires. These measures were performed at designated intervals during the first postoperative year. All patients received exercise and education, and patients with identified impairments underwent individualized rehabilitation intervention. Clinical factors associated with need for intervention were determined using univariate analysis. RESULTS: Thirty-six patients required rehabilitation intervention. There were no statistically significant differences between intervention and no-intervention groups for body mass index, breast surgery type, reconstruction type, or radiotherapy. Statistically significant differences were found between intervention and no-intervention groups in early postoperative UEFI, QuickDASH, pain scores, age, number of lymph nodes removed [9.3 (intervention) vs. 5.6 (no-intervention)], axillary surgery type, chemotherapy, and breast cancer stage. CONCLUSIONS: Survivorship practitioners should have heightened awareness for rehabilitation intervention in patients with greater axillary surgery and burden of disease. Patients with more activity restriction and lower levels of function in the early postoperative period may benefit from rehabilitation intervention. Future studies should focus on implementing a screening tool to identify patients in need of rehabilitation referral.

Ultrasound 2D Strain Estimator Based on Image Registration for Ultrasound Elastography.

In this paper, we present a new approach to calculate 2D strain through the registration of the pre- and post-compression (deformation) B-mode image sequences based on an intensity-based non-rigid registration algorithm (INRA). Compared with the most commonly used cross-correlation (CC) method, our approach is not constrained to any particular set of directions, and can overcome displacement estimation errors introduced by incoherent motion and variations in the signal under high compression. This INRA method was tested using phantom and in vivo data. The robustness of our approach was demonstrated in the axial direction as well as the lateral direction where the standard CC method frequently fails. In addition, our approach copes well under large compression (over 6%). In the phantom study, we computed the strain image under various compressions and calculated the signal-to-noise (SNR) and contrast-to-noise (CNS) ratios. The SNR and CNS values of the INRA method were much higher than those calculated from the CC-based method. Furthermore, the clinical feasibility of our approach was demonstrated with the in vivo data from patients with arm lymphedema.

Manipulative therapy of secondary lymphedema in the presence of locoregional tumors.

BACKGROUND: Complete decongestive therapy (CDT), including manual lymphatic drainage (MLD) is a manipulative intervention of documented benefit to patients with lymphedema (LE). Although the role of CDT for LE is well described, to the authors' knowledge there are no data regarding its efficacy for patients with LE due to tumor masses in the draining anatomic bed. Traditionally, LE therapists are wary of providing therapy to such patients with 'malignant' LE for fear of exacerbating the underlying cancer, and that the obstruction will render therapy less effective. In the current study, the authors' experience providing CDT for such patients is discussed. METHODS: Cancer survivors with LE were referred to therapists at 2 Atlanta-area clinics. CDT consists of treatment (Phase 1) and maintenance phases (Phase 2). During Phase 1, the patient undergoes manipulative therapy and bandaging daily until the LE reduction plateaus; at that point, Phase 2 (self-care) begins. At the beginning and end of Phase 1, LE is quantified and differences in girth volume calculated. The results for patients completing Phase 1 therapy for LE in the presence of locoregional masses were compared with results for patients with LE in the absence of such disease. Both volume reduction of the affected limb and number of treatments to plateau were analyzed. RESULTS: Between January 2004, and March 2007, LE of 82 limbs in 72 patients was treated with CDT and Phase 1 was completed. The median number of treatments to plateau was 12 (range, 4-23 treatments); the median limb volume reduction was 22% (range, -23 to 164%). Nineteen limbs (16 patients) with associated chest wall/axillary or pelvic/inguinal tumors had nonsignificant difference in LE reduction (P = .75) in the presence of significantly more sessions to attain plateau (P = .0016) compared with 63 limbs in 56 patients without such masses. CONCLUSIONS: Patients with LE may obtain relief with CDT regardless of whether they have locoregional disease contributing to their symptoms. However, it will likely take longer to achieve that effect. Manipulative therapy of LE should not be withheld because of persistent or recurrent disease in the draining anatomic bed.

Reduction of lymphedema using complete decongestive therapy: roles of prior radiation therapy and extent of axillary dissection.

Although radiation therapy (RT) contributes to lymphedema (LE), it is unknown whether RT contributes to more difficulty (more treatments) or less success (decreased LE reduction) with therapy for established LE. We reviewed the results of complete decongestive therapy (CDT) for LE with respect to a history of RT and the number of lymph nodes dissected. Breast cancer survivors with LE were referred to CDT-certified therapists. CDT consists of treatment (phase 1) and maintenance (phase 2) phases. During phase 1, the patient meets with a therapist daily until the LE reduction plateaus; then phase 2 (self-care) begins. During phase 1, LE is quantified weekly at a minimum. Fifty-three patients underwent CDT and completed phase 1. The median number of treatments to plateau was 12 (range 6-25); the median limb volume reduction was 36% (-4-119%). Thirty-six patients with an RT history had an insignificant difference in LE reduction (p = .49) and the number of sessions to plateau (p = .54) compared with 17 patients without RT. The median examined number of nodes was 12 (range 3-28). No significant correlation was observed between the number of nodes examined and percent reduction (r = -.390); no significant correlation (r = .291; critical r = .396 for p = .05 for both cases) was observed between the number of nodes sampled and the number of sessions to plateau. Patients with LE obtained relief regardless of whether they received surgery or surgery plus RT. The insignificant correlation between the number of lymph nodes and percent reduction could become significant with a larger sample size.